| Year |
Citation |
Score |
| 2008 |
Gobert D, Topolnik L, Azzi M, Huang L, Badeaux F, Desgroseillers L, Sossin WS, Lacaille JC. Forskolin induction of late-LTP and up-regulation of 5' TOP mRNAs translation via mTOR, ERK, and PI3K in hippocampal pyramidal cells. Journal of Neurochemistry. 106: 1160-74. PMID 18466337 DOI: 10.1111/J.1471-4159.2008.05470.X |
0.331 |
|
| 2007 |
Bourdeau ML, Morin F, Laurent CE, Azzi M, Lacaille JC. Kv4.3-mediated A-type K+ currents underlie rhythmic activity in hippocampal interneurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 1942-53. PMID 17314290 DOI: 10.1523/Jneurosci.3208-06.2007 |
0.641 |
|
| 2007 |
Charest PG, Oligny-Longpré G, Bonin H, Azzi M, Bouvier M. The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cellular Signalling. 19: 32-41. PMID 16857342 DOI: 10.1016/J.Cellsig.2006.05.020 |
0.758 |
|
| 2005 |
Costa-Mattioli M, Gobert D, Harding H, Herdy B, Azzi M, Bruno M, Bidinosti M, Ben Mamou C, Marcinkiewicz E, Yoshida M, Imataka H, Cuello AC, Seidah N, Sossin W, Lacaille JC, et al. Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature. 436: 1166-73. PMID 16121183 DOI: 10.1038/Nature03897 |
0.304 |
|
| 2005 |
Piñeyro G, Azzi M, deLéan A, Schiller PW, Bouvier M. Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human delta-opioid receptor with an inverse agonist. Molecular Pharmacology. 67: 336-48. PMID 15496503 DOI: 10.1124/Mol.104.004549 |
0.603 |
|
| 2003 |
Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Piñeyro G. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proceedings of the National Academy of Sciences of the United States of America. 100: 11406-11. PMID 13679574 DOI: 10.1073/Pnas.1936664100 |
0.685 |
|
| 2001 |
Azzi M, Piñeyro G, Pontier S, Parent S, Ansanay H, Bouvier M. Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. Molecular Pharmacology. 60: 999-1007. PMID 11641428 DOI: 10.1124/Mol.60.5.999 |
0.482 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2006 |
Topolnik L, Azzi M, Morin F, Kougioumoutzakis A, Lacaille JC. mGluR1/5 subtype-specific calcium signalling and induction of long-term potentiation in rat hippocampal oriens/alveus interneurones. The Journal of Physiology. 575: 115-31. PMID 16740609 DOI: 10.1113/Jphysiol.2006.112896 |
0.29 |
|
| 1994 |
Azzi M, Nicot A, Gully D, Kitabgi P, Bérod A, Rostène W. Increase in neurotensin receptor expression in rat brain induced by chronic treatment with the nonpeptide neurotensin receptor antagonist SR 48692. Neuroscience Letters. 172: 97-100. PMID 8084546 DOI: 10.1016/0304-3940(94)90671-8 |
0.253 |
|
| 1996 |
Azzi M, Boudin H, Mahmudi N, Pélaprat D, Rostène W, Bérod A. In vivo regulation of neurotensin receptors following long-term pharmacological blockade with a specific receptor antagonist. Brain Research. Molecular Brain Research. 42: 213-21. PMID 9013776 DOI: 10.1016/S0169-328X(96)00124-6 |
0.237 |
|
| 1994 |
Azzi M, Gully D, Heaulme M, Bérod A, Pélaprat D, Kitabgi P, Boigegrain R, Maffrand JP, LeFur G, Rostène W. Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists. European Journal of Pharmacology. 255: 167-74. PMID 8026542 DOI: 10.1016/0014-2999(94)90095-7 |
0.201 |
|
| 1998 |
Azzi M, Betancur C, Sillaber I, Spanagel R, Rostène W, Bérod A. Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. Journal of Neurochemistry. 71: 1158-67. PMID 9721741 DOI: 10.1046/J.1471-4159.1998.71031158.X |
0.176 |
|
| 1997 |
Betancur C, Azzi M, Rostène W. Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy. Trends in Pharmacological Sciences. 18: 372-86. PMID 9357322 DOI: 10.1016/S0165-6147(97)01109-7 |
0.163 |
|
| 2007 |
Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiology of Aging. 28: 537-47. PMID 16675063 DOI: 10.1016/J.Neurobiolaging.2006.02.015 |
0.135 |
|
| 1997 |
Rostène W, Azzi M, Betancur C, Pélaprat D, Gully D, Spanagel R, Bérod A. Neurotensin antagonists and dopaminergic function Biological Psychiatry. 42. DOI: 10.1016/S0006-3223(97)88098-5 |
0.087 |
|
| 2007 |
Azzi M, Yu M, Martin R, Bastien S, Martin S, Paquette J, Delorme D, Greenberg BD. P-187: Tramiprosate is neuroprotective and reduces the levels of secreted amyloid-β in organotypic hippocampal slice cultures Alzheimers & Dementia. 3. DOI: 10.1016/J.Jalz.2007.04.150 |
0.064 |
|
| 1997 |
Rostene W, Azzi M, Boudin H, Lepee I, Souaze F, Mendez-Ubach M, Betancur C, Gully D. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Annals of the New York Academy of Sciences. 814: 125-41. PMID 9160965 DOI: 10.1111/j.1749-6632.1997.tb46151.x |
0.063 |
|
| 2007 |
Morissette C, Lacombe D, Kong X, Aman A, Krzywkowski P, Rodionova L, Azzi M, Delorme D, Greenberg BD. Potential applications of glycosaminoglycan-related compounds in Alzheimer's disease Pharmacological Mechanisms in Alzheimer's Therapeutics. 255-273. DOI: 10.1007/978-0-387-71522-3_16 |
0.035 |
|
| Hide low-probability matches. |